Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma
NCT05353907 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 78
Last updated 2022-04-29
Summary
Up to 30% of patients with newly diagnosed/suspected myeloma cannot undergo or do not tolerate whole body MRI (WB-MRI). A number of factors may be contributory. First, WB-MRI protocols can take in excess of 1 hour. Patients must remain still within a narrow bore scanner with multiple MRI coils that can be claustrophobic. Second, there is significant acoustic noise that can be heard despite the use of ear protection. Third, 80% of patients will experience bone pain or fracture at some point during their illness, affecting their comfort within the scanner. Fourth, patients also have higher anxiety. One review reported up to 30% of patients experienced considerable apprehension and up to 10% severe psychological distress when undergoing MRI. Finally, myeloma is predominantly an illness of the elderly and co-morbid conditions decrease patients' ability to tolerate a long scan. When WB-MRI cannot be performed, NICE recommend whole-body computed tomography (WB-CT), which the investigators know offers decreased diagnostic performance in terms of marrow assessment and focal lesion detection. The investigators believe that using a novel CT technique - dual-energy CT (DECT) - may offer better diagnostic performance over standard WB-CT in myeloma patients.
What the investigators seek to do in this study is to evaluate the sensitivity and specificity of DECT in a cohort of untreated patients; and compare the performance of DECT to simulated standard CT (data simulated from the DECT) and also to WB-MRI (reference standard alongside bone marrow biopsy results. The investigators will assess both subjective visual analysis of DECT images as well as CT quantitative values for the bone marrow.
Secondary objectives include assessment of patient experience across both imaging tests and assessment of intra \& inter observer variability in subjective visual analysis
Conditions
Interventions
- RADIATION
-
Whole Body MRI
Once recruited, the participant will undergo a WB-MRI scan as part of their usual standard-of-care. As part of the research study, the participant will be consented to undertake an additional WB-DECT research scan at a time of their choosing (on the same day as the MRI scan, or on another day, if preferred)
Sponsors & Collaborators
-
Guy's and St Thomas' NHS Foundation Trust
lead OTHER
Principal Investigators
-
Vicky Goh · King's College London
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-30
- Primary Completion
- 2025-12-31
- Completion
- 2026-12-31
More Related Trials
-
Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors
NCT00581906 ·Status: ACTIVE_NOT_RECRUITING
-
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma
NCT02160925 ·Status: COMPLETED ·Phase: NA
-
Multimodal Imaging Analysis of Spinal Tumors
NCT04955522 ·Status: COMPLETED
-
The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids
NCT03993210 ·Status: TERMINATED ·Phase: NA
-
Non-invasive Glioma Characterization Through Molecular Imaging
NCT03684109 ·Status: RECRUITING ·Phase: NA
-
Retrospective Study on Leptomeningeal Metastasis of Solid Tumors
NCT06705049 ·Status: ENROLLING_BY_INVITATION
-
Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities
NCT00589095 ·Status: TERMINATED
-
AI-assisted Diagnosis of Malignant Brain Tumors
NCT07198256 ·Status: RECRUITING
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
NCT00870129 ·Status: RECRUITING ·Phase: NA
-
Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma
NCT05577884 ·Status: UNKNOWN
-
68Ga-DOTATATE Neuroblastoma Imaging Pilot
NCT04559217 ·Status: RECRUITING ·Phase: PHASE2
-
Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy
NCT02375334 ·Status: TERMINATED
-
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
NCT00285324 ·Status: COMPLETED
-
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma
NCT00756106 ·Status: TERMINATED ·Phase: NA
-
Optimal Timing of Postoperative Magnetic Resonance Imaging (MRI) in Patients With Extradural Spinal
NCT02790294 ·Status: COMPLETED ·Phase: NA
-
Multi-parametric Imaging in Personalized Radiotherapy
NCT05888064 ·Status: RECRUITING
-
Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma
NCT03168919 ·Status: TERMINATED ·Phase: NA
-
Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children
NCT05179850 ·Status: UNKNOWN
-
Radiomics for Prediction of Survival in GBM
NCT02666066 ·Status: COMPLETED
-
MR- PET Guided Biologically Optimised Interstitial Brachytherapy
NCT01391065 ·Status: COMPLETED ·Phase: NA
-
High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors
NCT02035852 ·Status: COMPLETED
-
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
NCT03820778 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
NCT00352521 ·Status: COMPLETED ·Phase: PHASE2
-
Advanced MRI Applications Development
NCT01847833 ·Status: UNKNOWN
-
Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
NCT02843230 ·Status: COMPLETED